Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2026
Reporting Period: Event-based report covering the closing of a major acquisition and executive leadership changes occurring on May 11-12, 2026.
Key Financial Metrics and Transaction Details
This filing reports a significant asset acquisition rather than standard periodic financial results (revenue, profit, or cash flow for a fiscal period are not provided in this document).
- Acquisition Consideration: Approximately $650 million in cash (subject to customary adjustments for net working capital, indebtedness, cash, and transaction expenses).
- Funding Sources:
- $350 million from existing cash on hand.
- $300 million from a delayed draw term loan under a syndicated credit facility announced in December 2025.
- Contingent Consideration: Up to $135 million in additional payments to the seller if AZSTARYS achieves specific future commercial and manufacturing milestones.
- Asset Acquired: AZSTARYS, a central nervous system stimulant prescription medicine for the treatment of ADHD in people 6 years of age and older.
Material Changes
Acquisition Completion: The Company completed the acquisition of GPC Commave Holding, LLC and Commave Sub, LLC from Corium Therapeutics Holdings, LLC and Corium, LLC. This transaction adds AZSTARYS to the Company's portfolio.
Executive Leadership Departures:
- Scott Dreyer: Executive Vice President and Chief Commercial Officer will depart effective August 30, 2026. Departure is treated as a termination without cause.
- Thomas Smith, M.D.: Executive Vice President and Chief Medical Officer will depart following a transition period. Departure is treated as a termination without cause.
Compensation Plan Adoption: The Board adopted the 2026 Inducement Plan, authorizing grants of up to 325,000 shares of common stock to new employees as an inducement material to their employment.
Guidance, Outlook, and Risks
Outlook: The acquisition of AZSTARYS is intended to expand the Company's commercial portfolio in the ADHD treatment space. Future financial impact will depend on the commercial performance of AZSTARYS relative to the $135 million in potential milestone payments.
Risks and Contingencies:
- Leadership Transition: The simultaneous departure of the Chief Commercial Officer and Chief Medical Officer introduces execution risk during the transition period.
- Debt Obligations: The transaction utilized $300 million in new debt financing, increasing the Company's leverage.
- Financial Reporting: Pro forma financial information and financial statements of the acquired business are not yet available and will be filed within 71 days of this report.
Investor Verification Checklist
- Verify the terms of the syndicated credit facility announced in December 2025 to understand interest rates and covenants associated with the $300 million draw.
- Review the specific commercial and manufacturing milestones required to trigger the $135 million contingent payment.
- Monitor the search process for successors to the departing Chief Commercial Officer and Chief Medical Officer.
- Check for the upcoming amendment to this 8-K (due within 71 days) for pro forma financial information and the acquired business's financial statements.
- Confirm the impact of the $350 million cash outflow on the Company's remaining liquidity position.